The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Kynan Feeney
No Relationships to Disclose
 
Myung Ah Lee
No Relationships to Disclose
 
Andres J. Muñoz Martín
Consulting or Advisory Role - Celgene; Sanofi
Speakers' Bureau - Shire/SERVIER
Research Funding - Celgene; Sanofi
Travel, Accommodations, Expenses - Celgene; Sanofi
 
Antonio Cubillo Gracián
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Roche
Research Funding - Amgen; Merck Serono
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Annie Hung
Stock and Other Ownership Interests - Omega Healthcare Investors
 
Yong Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Jacobio (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); TRACON Pharma (Inst); Tyrogenex (Inst)
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - Aduro Biotech; Amgen; ARMO BioSciences; Bristol-Myers Squibb; Cornerstone Pharmaceuticals; Gritstone Bio; Halozyme; Merck; Roche
Research Funding - Advaxis; Amgen; ARMO BioSciences; Halozyme; Merck; Merrimack